StreetInsider.com News Articles

Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm

Wed, 11 Mar 2026 09:00:00 -0400

LOS ANGELES, March 11, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aardvark Therapeutics, Inc., ("Aardvark" or the "Company") (NASDAQ:AARD) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/aardvark-therapeutics-inc. The Portnoy Law Firm can provide a complimentary case

Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm

Wed, 11 Mar 2026 09:00:00 -0400

Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm

Wed, 11 Mar 2026 09:00:00 -0400

Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm

Wed, 11 Mar 2026 09:00:00 -0400

Aardvark Therapeutics Inc (AARD) PT Lowered to $21 at Oppenheimer

Mon, 02 Mar 2026 08:06:12 -0400

Oppenheimer analyst Leland Gershell lowered the price target on Aardvark Therapeutics Inc (NASDAQ: AARD) to $21.00 (from $35.00) while maintaining a Outperform rating.

Aardvark Therapeutics Inc (AARD) PT Lowered to $21 at BofA Securities

Mon, 02 Mar 2026 07:29:11 -0400

BofA Securities analyst Tim Anderson lowered the price target on Aardvark Therapeutics Inc (NASDAQ: AARD) to $21.00 (from $25.00) while maintaining a Buy rating.

The analyst comments "AARD announced that it has voluntarily paused its Ph 3 HERO trial (and open-label extension) evaluating ARD-101 in Prader-Willi syndrome (PWS) following reversible cardiac observations at above-target therapeutic doses in a healthy volunteer study. AARD is choosing to pause while it conducts a full review of the data. As a result, the HERO topline data is no longer expected in 3Q26 (key catalyst for 2026). We await further details to understand broader implications for

Aardvark Therapeutics Inc (AARD) PT Lowered to $21 at BofA Securities

Mon, 02 Mar 2026 07:29:11 -0400

BofA Securities analyst Tim Anderson lowered the price target on Aardvark Therapeutics Inc (NASDAQ: AARD) to $21.00 (from $25.00) while maintaining a Buy rating.

H.C. Wainwright Downgrades Aardvark Therapeutics Inc (AARD) to Neutral

Mon, 02 Mar 2026 06:10:11 -0400

H.C. Wainwright analyst Raghuram Selvaraju downgraded Aardvark Therapeutics Inc (NASDAQ: AARD) from Buy to Neutral.

For an analyst ratings summary and ratings history on Aardvark Therapeutics Inc click here. For more ratings news on Aardvark Therapeutics Inc click here.

Shares of Aardvark Therapeutics Inc closed at $12.49 yesterday.

Aardvark Therapeutics Inc (AARD) PT Lowered to $9 at BTIG

Mon, 02 Mar 2026 06:07:50 -0400

(Updated - March 2, 2026 6:07 AM EST)

BTIG analyst Jeet Mukherjee lowered the price target on Aardvark Therapeutics Inc (NASDAQ: AARD) to $9.00 (from $26.00) while maintaining a Buy rating.

The analyst commented: "AARD stock is down ~50% after Friday's close following the co's announcement of a voluntary pause of the ph 3 HERO trial for ARD-101 for Prader Willi syndrome due to the observation of a reversible cardiac signal seen at above target doses in a healthy volunteer safety study to supplement NDA submission. Data from HERO was the key catalyst for the year, with the co no longer guiding

Aardvark Therapeutics Inc (AARD) PT Lowered to $9 at BTIG

Mon, 02 Mar 2026 06:07:50 -0400

(Updated - March 2, 2026 6:07 AM EST)

BTIG analyst Jeet Mukherjee lowered the price target on Aardvark Therapeutics Inc (NASDAQ: AARD) to $9.00 (from $26.00) while maintaining a Buy rating.

Stifel Downgrades Aardvark Therapeutics Inc (AARD) to Hold

Mon, 02 Mar 2026 02:53:57 -0400

Stifel analyst James Condulis downgraded Aardvark Therapeutics Inc (NASDAQ: AARD) from Buy to Hold with a price target of $6.00 (from $24.00).

The analyst comments: "Aardvark voluntarily paused their ph3 following "reversible cardiac observations" in a HV safety study and no longer plan to report data in 3Q. We spoke with management who noted reversible ECG signals occurred in a routine HV study at supra-therapeutic doses (1600mg BID). This hasn't been seen in prior preclinical/clinical studies--and regular safety monitoring of HERO has had no issues. They're meeting w/FDA where they're optimistic and would be surprised if there isn't a resolution-- though

Stifel Downgrades Aardvark Therapeutics Inc (AARD) to Hold

Mon, 02 Mar 2026 02:53:57 -0400

Stifel analyst James Condulis downgraded Aardvark Therapeutics Inc (NASDAQ: AARD) from Buy to Hold with a price target of $6.00 (from $24.00).

Morgan Stanley Downgrades Aardvark Therapeutics Inc (AARD) to Equalweight

Mon, 02 Mar 2026 02:38:49 -0400

Morgan Stanley analyst Michael E Ulz downgraded Aardvark Therapeutics Inc (NASDAQ: AARD) from Overweight to Equalweight with a price target of $7.00 (from $29.00).

The analyst comments: "On Friday after market close, Aardvark announced via press release (here) that it is voluntarily pausing its Ph3 HERO trial of ARD-101 in Prader-Willi syndrome (PWS) following reversible cardiac observations found during routine safety monitoring in the healthy volunteer (HV) study. We had a chance to catch up with mgt. who noted the observations were unexpected, not characterized as SAEs and were in a HV dose cohort notably above the target therapeutic dose used

Morgan Stanley Downgrades Aardvark Therapeutics Inc (AARD) to Equalweight

Mon, 02 Mar 2026 02:38:49 -0400

Morgan Stanley analyst Michael E Ulz downgraded Aardvark Therapeutics Inc (NASDAQ: AARD) from Overweight to Equalweight with a price target of $7.00 (from $29.00).

Morgan Stanley Downgrades Aardvark Therapeutics Inc (AARD) to Equalweight

Mon, 02 Mar 2026 02:38:49 -0400

Morgan Stanley analyst Michael E Ulz downgraded Aardvark Therapeutics Inc (NASDAQ: AARD) from Overweight to Equalweight with a price target of $7.00 (from $29.00).

Morgan Stanley Downgrades Aardvark Therapeutics Inc (AARD) to Equalweight

Mon, 02 Mar 2026 02:38:49 -0400

Morgan Stanley analyst Michael E Ulz downgraded Aardvark Therapeutics Inc (NASDAQ: AARD) from Overweight to Equalweight with a price target of $7.00 (from $29.00).

RBC Capital Downgrades Aardvark Therapeutics Inc (AARD) to Sector Perform

Mon, 02 Mar 2026 00:41:55 -0400

RBC Capital analyst Brian Abrahams downgraded Aardvark Therapeutics Inc (NASDAQ: AARD) from Outperform to Sector Perform with a price target of $6.00 (from $18.00).

The analyst comments: "On Friday evening, AARD announced a voluntary pause of the ongoing ph.III study of lead drug ARD-101 for Prader-Willi due to cardiac observations in a separate study of healthy subjects, and we had the chance to speak with mgmt. While the fact that clean safety was seen at therapeutic doses may still allow a path forward for the drug, timelines will likely be pushed back meaningfully as they engage with FDA on next steps,

RBC Capital Downgrades Aardvark Therapeutics Inc (AARD) to Sector Perform

Mon, 02 Mar 2026 00:41:55 -0400

RBC Capital analyst Brian Abrahams downgraded Aardvark Therapeutics Inc (NASDAQ: AARD) from Outperform to Sector Perform with a price target of $6.00 (from $18.00).

Form 8-K Aardvark Therapeutics, For: Feb 27

Fri, 27 Feb 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260227/26082400.html

Form 8-K Aardvark Therapeutics, For: Feb 27

Fri, 27 Feb 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260227/26082400.html

Aardvark Therapeutics pauses phase 3 trial due to cardiac safety signals

Fri, 27 Feb 2026 16:05:10 -0400

Aardvark Therapeutics Inc. (NASDAQ: AARD) announced it has voluntarily paused enrollment and dosing in its Phase 3 HERO trial evaluating ARD-101 for hyperphagia in patients with Prader-Willi Syndrome.

The company made the decision after observing reversible cardiac effects at above-target therapeutic doses during routine safety monitoring in a healthy volunteer study. Aardvark stated it is conducting a comprehensive review of the data to determine next steps.

"The safety of every patient in our clinical studies is our highest priority, so we will thoroughly evaluate the signals seen at higher than therapeutic doses of ARD-101 in a healthy volunteer study," said Tien Lee,

Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome

Fri, 27 Feb 2026 16:05:00 -0400

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. The HERO trial is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome (PWS).

The decision by Aardvark to voluntarily pause the HERO (NCT06828861) and open-label extension

Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome

Fri, 27 Feb 2026 16:05:00 -0400

The decision by Aardvark to voluntarily pause the HERO (NCT06828861) and open-label extension

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 13 Feb 2026 08:00:00 -0400

SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that (i) on February 9, 2026, five new employees were granted inducement awards consisting of stock options to purchase an aggregate of 147,213 shares of common stock and (ii) on February 11, 2026, one new employee was granted an inducement award consisting of a stock option to purchase 5,125 shares of common stock.

Each option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Inducement

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 13 Feb 2026 08:00:00 -0400

Each option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Inducement